A potent and selective inhibitor of a histone demethylase by England, K

Targeting histone lysine demethylases - Progress, challenges, and the future. by Thinnes, C, England, K, Kawamura, A, Chowdhury, R, Schofield, C, Hopkinson, R

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor by England, K, Tumber, A, Krojer, T, Scozzafava, G, Ng, S, Daniel, M, Szykowska, A, Che, K, von Delft, F, Burgess-Brown, N, Kawamura, A, Schofield, C, Brennan, P

Alzheimer’s disease drug discovery: targeting Dickkopf-1 induction of the Wnt-PCP non-canonical pathway by Johanssen, T, Wren, SP, Woffindale, C, Priestley, R, De Cesco, S, Ehebauer, MT, Dixon-Clarke, S, Katsouri, L, England, K, Bennet, JM, Fedorov, O, Brennan, PE, Di Daniel, E, Davis, JB

Potent and selective KDM5 inhibitor stops cellular demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells by Tumber, A, Nuzzi, A, Hookway, E, Hatch, S, Velupillai, S, Johansson, C, Kawamura, A, Savitsky, P, Yapp, C, Szykowska, A, Wu, N, Bountra, C, Strain-Damerell, C, Burgess-Brown, N, Ruda, G, Fedorov, O, Munro, S, England, K, Nowak, R, Schofield, C, La Thangue, N, Pawlyn, C, Davies, F, Morgan, G, Athanasou, N, Müller, S, Oppermann, U, Brennan, P

8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors by Bavetsias, V, Lanigan, R, Ruda, G, Atrash, B, McLaughlin, M, Tumber, A, Mok, N, Le Bihan, Y, Dempster, S, Boxall, K, Jeganathan, F, Hatch, S, Savitsky, P, Velupillai, S, Krojer, T, England, K, Sejberg, J, Thai, C, Donovan, A, Pal, A, Scozzafava, G, Bennett, J, Kawamura, A, Johansson, C, Szykowska, A, Gileadi, C, Burgess-Brown, N, von Delft, F, Oppermann, U, Walters, Z, Shipley, J, Raynaud, F, Westaway, S, Prinjha, R, Fedorov, O, Burke, R, Schofield, C, Westwood, I, Bountra, C, Müller, S, van Montfort, R, Brennan, P, Blagg, J